LexaGene to Present at Lytham Partners Virtual Investor Growth Conference
June 22 2020 - 8:50AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a biotechnology company that develops
genetic analyzers for rapid pathogen detection, is scheduled to
participate in a virtual presentation and fireside chat at the
Lytham Partners Virtual Investor Growth Conference on Wednesday,
June 24, 2020 at 1:00pm ET (10:00am PT).
A webcast of the presentation will be posted under the investor
relations section of LexaGene’s website at www.lexagene.com, or can
be accessed at
https://www.webcaster4.com/Webcast/Page/2419/35342 or
www.lythampartners.com/virtual. A replay of the presentation will
be available following the event.
Management will also be participating in virtual one-on-one
meetings on June 24 and 25, 2020. To arrange a meeting, please
contact Joe Dorame of Lytham Partners at dorame@lythampartners.com
or visit www.lythampartners.com/virtual.
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of Directors
Dr. Jack Regan Chief Executive Officer &
Director
About LexaGene Holdings Inc. LexaGene is a
biotechnology company that develops genetic analyzers for pathogen
detection and other molecular markers for on-site rapid testing in
veterinary diagnostics, food safety and for use in open-access
markets such as clinical research, agricultural testing and
biodefense. End-users simply need to collect a sample, load it onto
the instrument with a sample preparation cartridge, enter sample ID
and press ‘go’. The LX Analyzer delivers excellent sensitivity,
specificity, and breadth of detection and can return results in
about 1 hour. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
For further information, please contact:
Investor Relations Jay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024